Table 1. Demographic and baseline characteristics of study participants by vaccine group.
| 10μg Sm-TSP-2/Alhydrogel (N = 8) |
10μg Sm-TSP-2/Alhydrogel with AP 10–701 (N = 8) |
30μg Sm-TSP-2/Alhydrogel (N = 8) |
30μg Sm-TSP-2/Alhydrogel with AP 10–701 (N = 8) |
100μg Sm-TSP-2/Alhydrogel (N = 8) |
100μg Sm-TSP-2/Alhydrogel with AP 10–701 (N = 8) |
Euvax B Vaccine (N = 12) |
All (N = 60) |
||
|---|---|---|---|---|---|---|---|---|---|
| Sex | Male (n [%]) | 3 (38) | 3 (38) | 3 (38) | 4 (50) | 3 (38) | 1 (13) | 7 (58) | 24 (40) |
| Female (n [%]) | 5 (63) | 5 (63) | 5 (63) | 4 (50) | 5 (63) | 7 (88) | 5 (42) | 36 (60) | |
| Ethnicity | Hispanic/Latino (n [%]) | 8 (100) | 8 (100) | 8 (100) | 8 (100) | 8 (100) | 8 (100) | 12 (100) | 60 (100) |
| Race | Multi-Racial (n [%]) | 8 (100) | 8 (100) | 8 (100) | 8 (100) | 8 (100) | 8 (100) | 12 (100) | 60 (100) |
| Age (years) | Mean (SD) | 36.9 (8.0) | 37.8 (5.6) | 34.9 (9.3) | 30.1 (8.7) | 30.4 (8.1) | 33.9 (8.8) | 34.7 (7.7) | 34.1 (8.1) |
Note: N = Number of participants in the Safety Population; SD = standard deviation.